GlassScriptPhysician profile
Nicole C Antao
NPI 1942450986
$3,755.00
in general payments reported to CMS, 2019-2025
25 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.19 · 2022: $316 · 2023: $444 · 2024: $819 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $64.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.35 |
| Education | $64.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $571.91 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $415.43 | 2022-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $338.77 | 2022-2025 | Glassia |
| Genzyme Corporation | $336.95 | 2022-2025 | |
| Abbvie INC. | $334.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.86 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.10 | 2022-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $175.01 | 2024-2025 | Arikayce |
| Grifols USA, LLC | $162.62 | 2024-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $145.64 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $140.93 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $99.64 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $86.08 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Philips North America LLC | $66.12 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Verona Pharma, INC. | $61.76 | 2025 | Ohtuvayre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $41.71 | 2022 | |
| Mylan Specialty L.P. | $34.98 | 2022-2023 | Yupelri |
| Lilly USA, LLC | $23.67 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $22.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.30 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.52 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $17.40 | 2025 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $16.70 | 2024 | |
| Chiesi USA, INC. | $15.49 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Antao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.